This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.
Define what remains infected before choosing the treatment duration
Bone and joint infection is easiest to manage when the anatomy, microbiology, source-control plan, and treatment intent are named explicitly. Acute, subacute, and chronic describe tempo. They do not, by themselves, determine antibiotic duration.
The treatment examples concern adults with pyogenic bacterial infection. Mycobacterial, fungal, and Brucella infection require distinct regimens and durations. Pregnancy, major organ dysfunction, and concurrent bacteremia or endocarditis can change drug selection, route, and follow-up.
Scope for the live session
Teach through the core sections and three cases, then stop. The advanced section is a post-lecture reference for fellows, attendings, and questions that arise on service.
Learning objectives
- Obtain useful cultures and identify urgent source control.
- Separate native-joint infection, PJI, osteomyelitis, and chronic wound colonization.
- Choose route and duration from the operative plan, retained material, and treatment intent.
- Manage an open sacral wound without reflexively prescribing six weeks of antibiotics.
What changes the treatment plan?
A painful native knee, an infected knee prosthesis, and exposed sacral bone can all raise concern for infection. They pose different questions. Can the joint be drained? Must an implant stay in place? Can the wound be closed? The answers help determine whether antibiotics can cure the infection, control it, or treat only an acute complication.
Five questions organize every bone and joint infection
What is infected?Native joint, prosthesis, bone, spine, diabetic foot, pressure injury, or fracture hardware.
What is the best specimen?Blood, synovial fluid, bone, or multiple deep operative samples. A superficial wound swab rarely defines bone therapy.
What remains?Pus, necrotic bone, biofilm-coated implant, abscess, sinus tract, ischemic tissue, or an open wound.
Can it be controlled?Drain, debride, exchange, remove, reconstruct, revascularize, or manage noncuratively.
What is the intent?Cure, treatment with retained material, chronic suppression, or treatment of acute flares only.
Stable and unstable patients follow different clocks
If the patient is stable, obtain the highest-value specimen before antibiotics. If septic, hemodynamically unstable, or neurologically threatened, obtain blood cultures promptly but do not delay active therapy or urgent source control.
A hot native joint requires aspiration, drainage, and active antibiotics
Diagnose
Aspiration provides synovial fluid for bacterial culture, cell count with differential, and crystal analysis. Blood cultures help when fever, systemic illness, or the presentation suggests bacteremia. Finding crystals does not exclude infection, and no cell count alone settles the diagnosis.1
Initial coverage
After sampling, initial therapy usually covers staphylococci and streptococci. The Gram stain, likely source, host factors, and local resistance patterns determine whether gram-negative coverage is needed. With a negative Gram stain and no resistance risk, SANJO lists cefazolin plus ceftriaxone as one option.1 Vancomycin plus ceftriaxone is one empiric example when both MRSA and susceptible gram-negative bacilli need coverage. A credible risk of Pseudomonas changes the beta-lactam choice. Culture results guide narrowing.
Control the source
Large-joint infection usually requires urgent orthopedic drainage. Failure to improve should prompt reassessment of drainage, adjacent osteomyelitis, and the diagnosis before automatic broadening or extension.
Let the syndrome modify the empiric start| Clinical setting | Common pathogens | Practical implication |
| Typical adult native-joint infection | S. aureus and streptococci | Select antistaphylococcal coverage from MRSA risk and local epidemiology; add gram-negative coverage according to Gram stain, host, and source. |
| Older, immunocompromised, or suspected urinary/intra-abdominal source | Enteric gram-negative bacilli in addition to staphylococci and streptococci | Ensure gram-negative coverage and investigate the bloodstream source. |
| Injection drug use, healthcare exposure, or penetrating/water exposure | S. aureus; consider Pseudomonas according to exposure and local epidemiology | Use an antipseudomonal beta-lactam only when the risk is credible. |
| Migratory polyarthralgia, tenosynovitis, or pustules | Neisseria gonorrhoeae | Obtain NAAT from exposed mucosal sites and culture purulent material; treat with ceftriaxone. |
Duration
For a drained native joint in an improving adult, one expert approach is 1–2 weeks of IV therapy followed by 2–4 weeks of an active oral agent. Evidence for that precise IV interval is weak. Bacteremia, endocarditis, or adjacent osteomyelitis may determine the course instead. The trial supporting shorter treatment after drainage predominantly involved the hand and wrist.1,2
References 1, 2, 3
In PJI, the operation determines what antibiotics can accomplish
Establish the diagnosis
A sinus tract communicating with the prosthesis is diagnostic. If stable, aspirate before antibiotics when results will change management. At surgery, obtain multiple deep tissue cultures. Do not build months of therapy around a superficial wound or sinus swab.
Look for bacteremia
Obtain blood cultures with fever, systemic illness, acute hematogenous presentation, or suspected S. aureus. Search for the bloodstream source and complications when bacteremia is present.
PJI treatment pathways and antibiotic timing| Strategy | Best fit | Published guidance and decision points |
| DAIR with modular-component exchange | Acute symptoms, fixed implant, no sinus tract, acceptable soft tissue, and a usable biofilm-active oral regimen. | For susceptible staphylococcal PJI treated with DAIR, the archived 2013 IDSA regimen began with 2–6 weeks of pathogen-directed IV therapy plus rifampin. Rifampin then continued with an active oral companion to complete 3 months for a hip or 6 months for a knee. These are finite courses with curative intent. Route and duration depend on the patient, organism, operation, and regimen.4 |
| One-stage exchange | Selected chronic PJI with good soft tissue, known and tractable organism, and an experienced team. | For susceptible staphylococci, the historical regimen combines IV therapy with rifampin for 2–6 weeks, followed by rifampin with an active oral companion to complete 3 months. For other organisms, the published course is 4–6 weeks of pathogen-directed treatment. There is no common IV lead-in across these regimens.4 |
| Two-stage exchange: after explant and spacer | Chronic PJI, compromised tissue, difficult organism, or failed retention strategy. | After resection, the historical course is 4–6 weeks of an active IV or highly bioavailable oral agent. The patient’s course and the operative findings inform reimplantation timing; a fixed antibiotic-free interval is not established.4,5 |
| Reimplantation | Proceed when the clinical, surgical, and microbiologic assessment supports control. | Concordant positive deep cultures support persistent infection; a single virulent isolate can also be significant. Decide whether further therapeutic antibiotics are needed from the full operative and microbiologic assessment. With no residual infection, prolonged treatment is not automatic; indicated perioperative prophylaxis still applies. |
| No curative surgery | Operation is not feasible or is inconsistent with the patient's goals. | Treat acute sepsis or bacteremia first. Then consider chronic suppression only when there is a defined pathogen, a tolerable active oral drug, and a meaningful goal. It is noncurative. |
Use “suppression” precisely
Oral antibiotics after DAIR can still be part of an attempt at cure. The 3-month hip and 6-month knee courses above are finite regimens for susceptible staphylococci. Long-term suppression has a different goal: controlling infection when eradication is not feasible.4
Do not define DAIR candidacy by postoperative timing alone
Symptom duration, implant stability, sinus tract, soft tissue, pathogen, host factors, and ability to exchange modular components all affect the chance of cure.
References 4, 5, 6
Acute, subacute, and chronic osteomyelitis differ mainly in diagnostic and source-control problems
Use tempo to frame the problem, not to prescribe a duration| Pattern | Typical problem | Immediate priority |
| Acute | Hematogenous infection, contiguous spread, or acute postoperative infection. | Blood cultures when relevant, drain abscesses, obtain deep cultures, and start active therapy promptly when ill. |
| Subacute | Indolent vertebral infection or Brodie-type lesion; infection may mimic tumor or inflammatory disease. | If stable, obtain tissue for culture and histology before empiric therapy. |
| Chronic | Sequestrum, sinus tract, devitalized bone, ischemia, or retained hardware. | Define whether necrotic bone or hardware can be removed and whether soft-tissue coverage and perfusion can be restored. |
Route and anatomy predict the likely microbiology| Syndrome | Common pathogens | Sampling implication |
| Acute hematogenous long-bone or vertebral infection | S. aureus most common; streptococci and enteric gram-negative bacilli according to host and source | Blood cultures can be diagnostic. Evaluate S. aureus bacteremia for an endovascular source. |
| Post-traumatic, postoperative, or hardware-associated infection | S. aureus, coagulase-negative staphylococci, gram-negative bacilli; sometimes polymicrobial | Use multiple deep operative specimens, not a surface swab. |
| Contiguous diabetic foot osteomyelitis | Mild/new: S. aureus and beta-hemolytic streptococci. Chronic, deep, or previously treated: gram-negative bacilli and anaerobes become more likely. | Bone culture is preferred when feasible; superficial wound flora can mislead. |
| Pelvic osteomyelitis beneath a pressure injury | Often polymicrobial, but exposed bone and wound cultures are heavily colonized | Deep bone obtained during planned debridement/closure is the useful specimen. |
Source
Prefer blood cultures when hematogenous disease is plausible and bone or deep operative specimens when available. A superficial swab usually reflects colonizing flora.
Duration
For pyogenic osteomyelitis with adequate source control and no retained implant, the 2022 evidence review supports a maximum of 6 weeks. Complete removal of infected bone raises a different question: is there any remaining infection for antibiotics to treat? Evidence for omitting further bone-directed therapy in that setting is less certain.12
Route
Osteomyelitis does not automatically require a PICC. An active, well-absorbed oral regimen is reasonable when the patient is stable, source control is adequate, absorption is reliable, and adherence and interactions have been addressed.
Most bacterial vertebral infections are treated for 6 weeks.13 In the diabetic foot, surgery changes the estimate: 6 weeks is suggested when infected bone remains without resection, compared with up to 3 weeks after minor amputation with a positive bone-margin culture. Evidence for the foot durations is limited.14
References 8, 12, 13, 14
Diabetic foot osteomyelitis has a separate diagnostic and treatment pathway
Diagnose in sequence
Start with the clinical examination, probe-to-bone test, plain radiographs, and ESR or CRP when the examination is equivocal. Obtain MRI only when doubt persists. When culture will change treatment, obtain bone rather than superficial wound tissue.
Match empiric breadth to severity
For a mild infection in North America or Western Europe without recent antibiotics, target S. aureus and beta-hemolytic streptococci. Do not add empiric antipseudomonal therapy in a temperate climate unless prior cultures or a specific exposure makes it credible.
How surgery changes treatment in diabetic foot infection| Situation | Management |
|---|
| Complete resection of infected bone with no residual infection | A short course of 2–5 days is suggested after complete resection. Any remaining soft-tissue infection has a separate indication for treatment.14 |
| Minor amputation with positive bone-margin culture | Up to 3 weeks is suggested; the positive margin distinguishes this situation from complete resection.14 |
| Osteomyelitis without bone resection or amputation | A 6-week course is suggested when the infected bone is treated without resection or amputation.14 |
| Antibiotic-only approach | Reserve for selected forefoot osteomyelitis with no urgent drainage need, no peripheral arterial disease, and no exposed bone. |
| Moderate or severe diabetic foot infection | Severe infection warrants urgent surgical consultation. The same applies to moderate infection with extensive gangrene, necrotizing infection, suspected deep abscess, compartment syndrome, or severe ischemia. When an infected foot ulcer or gangrene coexists with PAD, obtain urgent surgical and vascular consultation to coordinate drainage and revascularization. For moderate or severe infection, the guideline suggests considering surgery within 24–48 hours with antibiotics to remove infected or necrotic tissue.14 |
Do not treat an uninfected ulcer. Offloading, debridement, wound care, perfusion assessment/revascularization, glycemic management, and footwear planning are core treatment, not adjuncts.
References 14
An open sacral wound without a closure plan is not cured by prolonged antibiotics
Three clinically different situations| Situation | Antibiotics | What matters more |
| Exposed bone or MRI changes, but no acute cellulitis, abscess, bacteremia, or sepsis; debridement and durable closure are not feasible. | Do not give a 6-week osteomyelitis course, repeated courses, or chronic suppression for the wound alone. | Pressure redistribution, wound and moisture care, selective debridement, nutrition, pain and odor control, continence management, and realistic goals of care. |
| New cellulitis, drainable collection, pyomyositis, bacteremia, or sepsis. | Treat the acute syndrome and narrow to meaningful cultures. Duration follows that syndrome and source control, not the chronic MRI finding. | Drain collections, debride when appropriate, and assess for other sources. |
| Debridement and flap closure are planned. | Obtain deep bone specimens after debridement and use targeted therapy. About 6 weeks remains conventional when osteomyelitis is confirmed, although evidence is limited. | One coordinated surgical, wound, nutrition, pressure-relief, and rehabilitation plan. |
Exposed bone and MRI are not enough
Exposed bone may show remodeling without histologic osteomyelitis, and MRI can overcall infection in chronic pressure injury. Antibiotics without debridement and closure have not shown durable benefit.
References 15, 16
Antibiotic route and duration follow source control, not the imaging label
IV-to-oral transition · When outpatient IV therapy is needed
Before treatment
Obtain the best specimen first when the patient is stable. Start empiric therapy promptly when unstable, then narrow to the organism and operative findings.
Before oral transition
Confirm clinical stability, adequate source control, an active oral drug with appropriate exposure, reliable absorption and adherence, and manageable interactions and toxicities.
Before extending
Reassess drainage, retained material, ischemia, wound closure, an alternative diagnosis, and drug exposure. Persistent imaging abnormalities alone do not prove failure.
Before suppressing
Name the unremovable infected source, organism, active oral option, monitoring plan, expected benefit, and stop criteria. Suppression is not simply an extra-long curative course.
Three cases are enough for the live discussion
Case 1 · Crystals in a hot native knee
A febrile patient has an acutely swollen knee. Synovial fluid contains urate crystals and 72,000 WBC/µL with 92% neutrophils.
What should happen next?
Crystals do not exclude infection. Send synovial culture and blood cultures, begin empiric therapy after aspiration if stable enough to sample first, and obtain urgent orthopedic input for drainage.
Case 2 · Acute postoperative knee PJI
Three weeks after TKA, the patient develops 3 days of pain, effusion, and drainage. Components are fixed and aspiration grows MSSA.
What determines the plan?
The brief symptom history and fixed components favor DAIR if there is no sinus tract, the soft tissue is suitable, and modular components can be exchanged. Multiple deep cultures define what remains to be treated. For susceptible MSSA in a retained knee prosthesis, the 6-month rifampin-based regimen aims at cure. Rifampin requires an active companion after debridement; the oral transition depends on the patient’s response.4
Case 3 · Exposed sacral bone without a flap option
A chronically immobile patient has an open stage IV sacral wound and MRI changes called osteomyelitis, but no cellulitis, abscess, fever, bacteremia, or instability. Durable closure is not feasible.
Would six weeks of antibiotics help?
No durable benefit has been shown. Do not treat the imaging label alone. Focus on pressure relief, wound and moisture care, nutrition, debridement when appropriate, symptom control, and goals of care. Treat future discrete cellulitis, abscess, bacteremia, or sepsis episodes when they occur.
Closing sentence
Name the infected structure, best microbiology, source control completed or impossible, retained material, treatment intent, and the event that determines duration.
Advanced and reference material begins here
The live 30–45 minute lecture ends above. Use the sections below for fellow-level discussion, organism-specific decisions, uncommon syndromes, evidence review, extra cases, and self-study.
Classify five things before selecting an antibiotic
What structure?Native joint, prosthesis, bone, spine, diabetic foot, pressure injury, fracture hardware.
What tempo?Hours to days, weeks, or months. Tempo narrows the differential but does not set the treatment clock.
What remains?Pus, necrotic bone, biofilm-coated implant, sinus tract, unstable spine, open wound, ischemic tissue.
Can it be controlled?Drain, debride, exchange, remove, reconstruct, revascularize, or intentionally manage noncuratively.
What is the intent?Cure, prolonged treatment with retained material, suppression, or treatment of acute flares only.
Tempo changes the differential more than it changes the duration
| Pattern |
Common examples |
What it should trigger |
What it does not prove |
| Acute |
Hot native joint, acute hematogenous osteomyelitis, early postoperative PJI, acute hematogenous PJI |
Urgent aspiration/cultures, assessment for bacteremia, prompt drainage or debridement when indicated |
That a short antibiotic course will be sufficient |
| Subacute |
Brodie abscess, indolent vertebral infection, delayed PJI |
Deliberate tissue diagnosis, histology when mimic is possible, surgical planning before empiric therapy if stable |
That normal WBC/CRP excludes infection |
| Chronic |
Sinus-tract PJI, sequestrum, chronic post-traumatic osteomyelitis, stage IV pressure injury |
Identify necrotic bone or retained material and decide whether durable source control is feasible |
That prolonged antibiotics alone can sterilize an uncorrected source |
Do not let the MRI choose the treatment
MRI is sensitive for osteomyelitis but can remain abnormal during healing and can be difficult to interpret near surgery, hardware, neuropathic bone, or chronic pressure injury. Treat a clinical syndrome with a source-control plan, not an imaging phrase in isolation.
References 12, 15, 16
Native septic arthritis is a drainage problem plus an antibiotic problem
Before antibiotics
Unless the patient is septic or unstable, aspirate the joint promptly before starting antibiotics. Send synovial bacterial culture, cell count with differential, and crystals; obtain blood cultures when febrile, systemically ill, or bacteremia is plausible. A synovial WBC above 50,000/µL increases suspicion but is not diagnostic, a lower count does not exclude infection, and crystals do not exclude concomitant bacterial arthritis.
Gram stain has limited sensitivity but useful specificity. If the joint is difficult to access, image-guided aspiration is reasonable. Sacroiliac, sternoclavicular, and other axial infections deserve early assessment for adjacent osteomyelitis, abscess, or endovascular source.
Practical adult native-joint treatment framework
| Situation |
Initial approach |
Source control |
Typical duration framework |
| Unstable, sepsis, or septic shock |
Obtain blood cultures and aspirate if this will not meaningfully delay therapy. Vancomycin plus ceftriaxone is an empiric example when both MRSA and susceptible gram-negative bacilli need coverage. Consider broader gram-negative coverage when the resistance risk or exposure warrants it. Tailor coverage to prior isolates and the local antibiogram. |
Urgent orthopedic evaluation and lavage/drainage. |
Define after organism, drainage, bacteremia, and adjacent infection are known. |
| Stable, no resistant gram-negative risk |
Aspiration comes first in a stable patient. With a negative Gram stain and no risk of resistant organisms, options include cefazolin (or an antistaphylococcal penicillin) plus ceftriaxone, or amoxicillin-clavulanate. MRSA risk or local resistance can change initial coverage; cultures permit narrowing.1 |
Arthroscopic lavage is commonly preferred for large joints; open debridement may be needed for advanced disease, adhesions, or bone/cartilage destruction. |
One approach, supported by limited evidence, is 1–2 weeks IV followed by 2–4 weeks orally once symptoms and inflammatory markers improve. An effective oral option and adequate drainage matter more than reaching a fixed switch date. The shorter-course trial predominantly enrolled hand and wrist infections.1,2 |
| MSSA |
Cefazolin or an antistaphylococcal penicillin. |
Drainage remains essential. |
Usually measured in weeks, not days. Extend for bacteremia complications, adjacent osteomyelitis, delayed drainage, or poor response. |
| MRSA |
Vancomycin or daptomycin when appropriate; tailor to susceptibility, renal function, bacteremia, and local practice. |
Drainage remains essential. |
Expert guidance published in 2011 suggested 3–4 weeks for drained MRSA septic arthritis. Concurrent bacteremia, endocarditis, or adjacent osteomyelitis has its own treatment requirements.11 |
| Streptococci |
Penicillin/ampicillin or ceftriaxone when susceptible. |
Drainage. |
Usually several weeks; clinical response and complexity matter. |
| Enteric gram-negative bacilli |
Ceftriaxone, cefepime, a carbapenem, or other active beta-lactam according to resistance pattern and syndrome. Active fluoroquinolone or TMP-SMX can be oral completion options in selected patients. |
Drainage; investigate urinary, abdominal, or bloodstream source when appropriate. |
Duration depends on drainage, response, and whether the joint is the only infected site. A concurrent endovascular or bone infection can determine the course. |
| Pseudomonas |
Active cefepime, ceftazidime, piperacillin-tazobactam, or another susceptibility-guided antipseudomonal agent; ciprofloxacin can be a high-bioavailability oral option if susceptible and clinically appropriate. |
Drainage. |
The organism determines which drugs are active. Duration also depends on drainage, clinical response, and any associated bone or bloodstream infection; isolation of Pseudomonas alone does not define the course. |
| Gonococcal arthritis / arthritis-dermatitis |
Treatment of gonococcal arthritis begins with parenteral ceftriaxone. A single injection for uncomplicated mucosal gonorrhea is insufficient. If chlamydia has not been excluded, the accompanying treatment is doxycycline for 7 days in nonpregnant adults or azithromycin in pregnancy, with pregnancy-specific follow-up. |
Purulent joints may require serial aspiration or operative drainage. |
For arthritis-dermatitis syndrome, oral treatment becomes an option 24–48 hours after substantial clinical improvement when susceptibility testing identifies an active oral drug. Total treatment is at least 7 days.3 |
The two-week trial is easy to overgeneralize
A randomized trial found 2 weeks noninferior to 4 weeks after surgical drainage, but 99 of 154 cases involved the hand or wrist. It should not be used as blanket evidence for two weeks in a bacteremic native knee, shoulder, hip, axial joint, or infection with adjacent osteomyelitis.
Failure to improve should trigger repeat examination and reassessment of drainage, not automatic broadening or extension.
References 1, 2, 3
PJI diagnosis starts with timing, implant status, and the quality of the specimen
The 2021 EBJIS framework classifies PJI as infection unlikely, likely, or confirmed. A sinus tract that communicates with the prosthesis confirms PJI.18 Acute pain in a previously well-functioning prosthesis, persistent drainage, unexplained chronic pain, or loosening should trigger evaluation. ESR and CRP are useful screening tests when the diagnosis is not already obvious, but normal markers do not exclude indolent PJI.
Preoperative sampling
Aspirate the joint when the diagnosis is uncertain or when microbiology will change treatment. Send synovial cell count/differential and aerobic/anaerobic cultures. Exact cutoffs vary by joint, time from implantation, and criteria set.
If clinically stable
Avoid starting empiric therapeutic antibiotics just because PJI is suspected. When medically safe, withholding therapeutic antibiotics for at least 2 weeks before aspiration or operative cultures can improve yield. Coordinate indicated perioperative prophylaxis separately with the surgical team.4
At surgery
At revision surgery, EBJIS advises obtaining at least 5 deep tissue specimens with separate instruments for aerobic and anaerobic culture. IDSA specifies at least 3 and ideally 5–6. Use deep cultures to guide prolonged therapy.184
Adjunct diagnostics
Synovial alpha-defensin, leukocyte esterase, optimized culture techniques, histopathology, sonication, and molecular methods can help in selected culture-negative or equivocal cases. None converts a low-quality specimen into a definitive etiologic diagnosis.
References 4, 5
The operation determines the antibiotic strategy in PJI
Operative pathways and antibiotic timing
| Strategy |
Best fit |
Immediate postoperative phase |
Total course and reimplantation plan |
| DAIR with modular-component exchange |
Implant retention is most plausible when the prosthesis is well fixed, there is no sinus tract, and either implantation was within about 30 days or symptoms began less than 3 weeks ago. Tissue quality, microbiology, and available antibiotics also influence the chance of cure.4,5 |
Open debridement with polyethylene/modular exchange when feasible. Use pathogen-directed therapy; an active oral transition depends on the organism, patient, surgical response, and regimen. For susceptible staphylococci, use rifampin only with an active companion after debridement. |
For susceptible staphylococci, the archived 2013 regimen began with 2–6 weeks of pathogen-directed IV therapy plus rifampin, followed by rifampin with an active oral companion to complete 3 months for a hip or 6 months for a knee. This was a finite course with curative intent. Other organisms and regimens require separate duration decisions.4 |
| One-stage exchange |
Selected chronic PJI with good soft tissue, no sinus tract or major reconstructive barrier, and a known, susceptible, readily treatable organism. |
Remove all infected components, perform radical debridement, obtain at least 5 deep specimens with separate instruments, and implant the new prosthesis in the same operation. Use organism-directed therapy. Transition to an active oral agent may be appropriate, but no fixed IV lead-in applies to all cases. |
For susceptible staphylococci, the published regimen combines 2–6 weeks of IV therapy with rifampin, then rifampin with an active oral companion to complete 3 months. For other organisms, the corresponding course is 4–6 weeks of pathogen-directed treatment. A decision to suppress infection indefinitely is separate.4 |
| Two-stage exchange: first stage |
Chronic PJI, compromised soft tissue, difficult or unknown organism, major bone loss, or failed DAIR/one-stage strategy. |
Prosthesis removal and debridement provide deep specimens; an antibiotic spacer may be placed. The pathogen, susceptibility, and available drug exposures determine whether IV or highly bioavailable oral therapy is suitable.4 |
The published course is 4–6 weeks after resection. Neither the need for an antibiotic-free period nor its optimal length before reimplantation has been established.4,5 |
| Two-stage exchange: reimplantation |
Clinical course, soft tissue, surgical findings, inflammatory markers, and any aspiration/culture data support infection control. |
Obtain multiple deep specimens at reimplantation. Give indicated perioperative surgical prophylaxis when the prior infection is believed eradicated. This is distinct from restarting a prolonged therapeutic course; base that decision on operative findings, microbiology, and the joint-team assessment. |
Concordant growth in at least 2 specimens supports persistent infection. Do not dismiss a single virulent isolate such as S. aureus; interpret it with histology, operative findings, and the joint-team assessment. Decide the need and duration of additional treatment case by case. Negative cultures without residual infection do not by themselves justify prolonged postoperative therapy. |
| Resection arthroplasty / arthrodesis |
When reconstruction is not feasible, repeated curative attempts have failed, or patient goals favor this operative strategy. |
Obtain deep cultures and define residual bone, soft-tissue infection, and any retained fixation. Route depends on the organism, exposure, patient, and surgical result. |
After resection arthroplasty, 4–6 weeks of pathogen-directed treatment is the usual published course, whether or not reimplantation is planned. With arthrodesis, the key questions are what fixation remains and whether infection was completely removed.4 |
| Amputation for PJI |
The operation removes the infected limb segment; document whether infected bone or soft tissue remains. |
Assess concurrent bacteremia or sepsis separately. |
If amputation removes all infected bone and soft tissue and there is no bacteremia or sepsis, expert guidance suggests only 24–48 hours of pathogen-directed therapy after surgery. If infected bone and soft tissue remain, it suggests 4–6 weeks. Isolated soft-tissue infection, bacteremia, or sepsis has its own treatment requirements. These estimates rest on expert opinion.4 |
| No curative surgery |
Operative risk, patient preference, or anatomy makes curative source control unacceptable. |
Treat acute sepsis, abscess, or bacteremia first and obtain the best possible microbiology. |
Then consider culture-directed suppressive therapy only if there is a defined organism, active tolerable oral option, and meaningful functional goal. Suppression is noncurative and can fail from resistance, toxicity, loosening, sinus formation, or progression. |
Published DAIR regimens and duration evidence
The 3-month hip and 6-month knee courses apply specifically to susceptible staphylococci treated with a rifampin-based regimen after DAIR.4 DATIPO asked a different question: across surgically managed PJI, 6 weeks did not meet the trial’s criterion for noninferiority to 12 weeks. It did not establish one duration for every organism or operation.6
Do not overgeneralize SOLARIO
SOLARIO found that no more than 7 days of systemic antibiotics was noninferior to at least 4 weeks after definitive curative surgery plus a licensed local-antibiotic carrier with at least 4 weeks of elution. DAIR, suppressive procedures, and infections with bacteria fully resistant to the local antibiotics were excluded. The PJI subgroup was small and not independently powered. The result may inform selected definitive operations with the same local-antibiotic and closure conditions. It does not support short systemic therapy after DAIR, and it does not independently establish an optimal course for every one-stage or two-stage exchange.
Rifampin rules
- Use rifampin for a susceptible staphylococcal biofilm infection only as part of combination therapy. Never use rifampin monotherapy.
- Do not add it empirically before knowing the organism. Reduce the bacterial burden surgically first.
- Review drug interactions, hepatotoxicity, absorption, and companion-drug activity. Fluoroquinolones have the strongest companion evidence, but other agents are used when appropriate.
- The exact best time to start rifampin is not established. A rigid postoperative day rule is not evidence based.
References 4, 6, 9, 12, 5
What remains after debridement determines how duration evidence applies
First define the route and anatomy: hematogenous, contiguous/post-traumatic, diabetic foot, vertebral, pressure-injury pelvic osteomyelitis, or hardware-associated infection. Chronic osteomyelitis with a sequestrum behaves differently from acute hematogenous disease even if the same organism is isolated.
Management by source-control state
| Scenario |
Diagnostic priority |
Non-ID treatment |
Antibiotic duration framework |
| Acute hematogenous osteomyelitis |
Blood cultures; MRI when needed; tissue diagnosis if blood cultures do not establish the pathogen and biopsy will change management. |
Drain abscess; debride necrotic tissue when present. Evaluate endovascular source for S. aureus bacteremia. |
A course of up to 6 weeks is supported for pyogenic infection with adequate source control and no retained implant. Route depends on an active, adequately absorbed drug; bloodstream or endovascular infection may set different requirements.12 |
| Subacute osteomyelitis / Brodie abscess |
Imaging plus biopsy/curettage when feasible because tumor and other mimics can resemble infection. Systemic inflammatory signs are often absent. |
Curettage/debridement is common, both diagnostic and therapeutic. |
There is no high-quality duration standard. Published cases used courses ranging from 10 days to more than 3 months, often with surgery.17 |
| Chronic contiguous or post-traumatic osteomyelitis with sequestrum |
Deep bone/tissue culture and histology at debridement. Surface swabs are weak etiologic specimens. |
Remove necrotic bone, drain abscess, manage dead space, remove infected hardware when feasible, stabilize bone, and obtain durable vascularized soft-tissue coverage. |
With adequate debridement and no retained implant, evidence supports a maximum of 6 weeks. Courses of 3–4 weeks have been studied after debridement, but the evidence for that shorter duration is less certain.12 |
| Complete resection of infected bone |
Confirm that residual infected bone and soft-tissue infection are absent. |
Definitive resection/amputation plus wound management. |
When all infected bone is confidently removed, the 2022 review considers omission of further bone-directed therapy reasonable, but the supporting evidence is limited.12 The diabetic-foot-specific guideline lists 2–5 days after complete resection.14 Neither estimate covers residual bone or soft-tissue infection, a retained implant, or bacteremia. |
| Retained fracture fixation hardware |
Deep cultures, union status, stability, and whether hardware can be removed without mechanical failure. |
Debridement and stabilization. Sometimes hardware must remain until union, then can be removed. |
If the fixation must stay in place, a usable biofilm-active regimen may permit an attempt at cure after debridement. Where cure is unlikely, suppression can sometimes bridge the patient to union and safe removal. That strategy depends on a stable construct and a realistic prospect of healing.10 |
Diabetic foot osteomyelitis deserves its own pathway
The initial assessment combines a probe-to-bone test, plain radiographs, and an inflammatory marker such as ESR, CRP, or procalcitonin. MRI is useful when uncertainty remains. Bone culture, when feasible, can identify pathogens missed or misrepresented by a superficial specimen. In mild infection in North America or Western Europe without recent antibiotics, empiric coverage generally targets aerobic gram-positive pathogens. Pseudomonas coverage is not routine in temperate climates; prior cultures and exposures inform the individual assessment.14
When infected bone is treated without resection or amputation, a 6-week course is suggested. A positive bone-margin culture after minor amputation supports a shorter course of up to 3 weeks; both estimates rest on low-certainty evidence. Antibiotics alone may be reasonable for selected forefoot infections without exposed bone, peripheral arterial disease, or an urgent need for drainage. Severe infection warrants urgent surgical consultation. The same applies to moderate infection with extensive gangrene, necrotizing infection, suspected deep abscess, compartment syndrome, or severe ischemia. When an infected foot ulcer or gangrene coexists with PAD, obtain urgent surgical and vascular consultation to coordinate drainage and revascularization. For moderate or severe infection, the guideline suggests considering surgery within 24–48 hours with antibiotics to remove infected or necrotic tissue. Offloading, wound care, and glycemic management remain essential.14
Oral is a pharmacologic decision, not a concession
For a stable patient with adequate source control, reliable absorption, and an active high-bioavailability regimen with clinical evidence, a PICC is not required solely because the diagnosis is osteomyelitis. OVIVA directly supports oral therapy for appropriately selected complex bone and joint infections.
References 12, 8, 14, 17
Stable vertebral osteomyelitis is one of the situations where delaying empiric therapy can improve the diagnosis
Blood cultures and MRI can establish the diagnosis when S. aureus bacteremia accompanies compatible spinal findings. When cultures are negative, a normal, stable neurologic examination and stable hemodynamics can allow time for biopsy before empiric treatment. Suspected vertebral infection with neurologic compromise requires immediate spine surgical evaluation and empiric antimicrobial therapy. Sepsis or shock also calls for prompt empiric therapy while diagnostic sampling proceeds if feasible.13
Medical treatment
Most adults with bacterial native vertebral osteomyelitis receive 6 weeks of parenteral or highly bioavailable oral therapy.20 Brucella, mycobacterial, and fungal infections require separate regimens. Some experts extend treatment for extensive or otherwise high-risk infection, but evidence of benefit is limited. Persistent MRI abnormalities alone do not justify a longer course.13
Other reasons for spine surgical review
Progressive deformity, spinal instability, persistent or recurrent bacteremia without another source, or worsening pain despite appropriate therapy.
Follow the patient clinically. ESR/CRP can support trend assessment, but persistent pain, an elevated marker, or residual MRI abnormalities alone do not establish treatment failure.
References 13
Chronic sacral or pelvic osteomyelitis with an open pressure wound is not a six-week-antibiotic diagnosis
Exposed bone does not prove osteomyelitis. Chronically exposed bone can show reactive remodeling, and MRI may not reliably distinguish that from infection. If the wound cannot be debrided and durably closed, evidence has not shown that prolonged antibiotics sterilize the underlying bone or improve durable outcomes. The treatment goal becomes wound stability, symptom control, prevention of new pressure injury, and treatment of discrete acute infections.
Stage IV sacral/pelvic pressure injury: when antibiotics help and when they do not
| Clinical scenario |
Systemic antibiotics |
What matters more |
| Exposed bone, chronic wound, no cellulitis, abscess, bacteremia, or systemic illness; no plan for debridement/flap closure |
None. Do not treat the exposed bone or MRI result with a chronic osteomyelitis course. |
Pressure redistribution, wound cleansing/dressings and exudate control, debridement of devitalized tissue when appropriate, moisture/incontinence management, nutrition, pain/odor control, rehabilitation and caregiver feasibility, and goals of care. |
| Pelvic osteomyelitis suspected or diagnosed, but no soft-tissue infection and no plan for debridement plus flap reconstruction |
None. Current evidence does not support prolonged systemic antibiotics. |
Reassess whether closure is feasible with plastics/wound surgery. If not, manage the chronic wound rather than trying to sterilize an open contaminated surface. |
| Acute cellulitis/soft-tissue infection extending from the ulcer, no abscess |
Five days is reasonable for improving cellulitis. Extend if clinical improvement is slow. Choose coverage from severity, prior cultures, healthcare exposure, and local ecology.19 |
Debride necrotic tissue if needed, optimize wound care, pressure relief, and evaluate for deeper collection. |
| Drainable cutaneous abscess |
Drain first. If adjunctive antibiotics are indicated, a pressure-injury review describes 5–10 days after drainage for a cutaneous abscess. Deeper or systemic infection can change the course.16 |
Drainage is the key intervention. Obtain a meaningful deep specimen. |
| Pyomyositis |
Begin with IV therapy and promptly drain purulent collections. A 2–3-week course with possible oral completion is appropriate when the patient improves, any bacteremia clears promptly, and there is no endocarditis or metastatic abscess.19 |
Persistent bacteremia warrants reassessment for undrained infection and other foci. |
| Sepsis or bacteremia plausibly arising from an infected pressure injury |
Sepsis requires prompt empiric therapy; obtain blood or deep cultures first when this will not delay treatment. If MRSA, gram-negative, and anaerobic coverage are all needed, examples include vancomycin plus cefepime and metronidazole, or vancomycin plus piperacillin-tazobactam. Prior isolates, local susceptibility, allergies, and organ function inform the initial choice; meaningful cultures guide narrowing. |
Look for abscess, necrotizing infection, fecal/urinary contamination, or another source. Treat the systemic syndrome and source. Do not automatically convert clinical improvement into six weeks of therapy. |
| Debridement and flap reconstruction planned |
When stable, hold unnecessary empiric antibiotics until operative deep bone/tissue cultures if feasible. After adequate debridement and flap coverage, 6 weeks remains a conventional standard. Selected cortical-only disease may need less, but evidence for 2–4 weeks is not yet strong enough to use as a universal default. |
Multidisciplinary surgery, durable coverage, pressure offloading, nutritional optimization, continence management, and a realistic postoperative pressure-relief plan. |
Do not substitute suppressive antibiotics for wound closure
Long-term suppression is sometimes rational for a retained infected orthopedic implant or extensive necrotic bone that cannot be removed. That logic should not be automatically transferred to an open stage IV sacral wound. Ongoing contamination and absent coverage make durable microbial suppression unlikely, and the best available reviews recommend no systemic antibiotics in the absence of an acute soft-tissue/systemic infection or a reconstructive surgical plan.
Non-ID treatment is the treatment
Pressure and wound mechanics
Regular pressure redistribution/repositioning, appropriate support surface, minimizing shear, absorbent dressings, moisture balance, and reducing dressing trauma/frequency when palliation is the goal.
Debridement and reconstruction
Wound surgery/plastics evaluation for debridement, bone resection when needed, and flap coverage. Assess whether postoperative offloading and wound protection are realistically sustainable before major reconstruction.
Host optimization
Nutrition and protein/calorie adequacy, perfusion, smoking cessation when relevant, glycemic management, management of spasticity/contractures, urinary/fecal incontinence, pain, odor, mobility, and caregiver resources.
References 15, 16
Choose the antibiotic from the pathogen, site, retained material, and route plan
MRSA and VRE treatment considerations · Beta-lactam selection with a penicillin allergy label
A drug’s role matters as much as its activity against an isolate. Completing a finite course, serving as a rifampin companion, and suppressing infection in retained material are different uses. Deep specimens, the operation performed, susceptibility, and achievable exposure help distinguish them. Renal and hepatic function, allergies, interactions, and the feasibility of monitoring shape the final choice.
Pathogen clues and common definitive choices
| Pathogen |
Common definitive options |
Oral options requiring a defined treatment phase |
Special issue |
MSSA Acute native joint, acute hematogenous osteomyelitis, early or hematogenous PJI |
Cefazolin, nafcillin, or oxacillin. |
Selected patients can complete with a clinically validated active oral regimen. For retained staphylococcal prostheses, rifampin-combination strategy is a separate biofilm decision. |
A positive blood culture changes the workup. |
MRSA Same syndromes as MSSA; risk rises with prior colonization/infection and healthcare exposure |
Vancomycin or daptomycin; other agents depend on syndrome and susceptibility. |
Linezolid, TMP-SMX, or doxycycline/minocycline can be used in selected bone/joint regimens when active and clinically appropriate. |
Check bacteremia/endocarditis, drug toxicity, MIC context, and retained hardware. |
Coagulase-negative staphylococci Indolent postoperative infection and chronic PJI |
Vancomycin initially when methicillin resistance is possible; use cefazolin or an antistaphylococcal penicillin if susceptible. |
Doxycycline/minocycline, TMP-SMX, linezolid, or a beta-lactam when susceptible and clinically appropriate. |
Repeated concordant deep cultures help distinguish pathogen from contamination. Consider rifampin combination therapy when susceptible staphylococcal hardware is retained. |
Cutibacterium acnes Especially indolent shoulder PJI |
Penicillin G or ceftriaxone are common IV choices. |
For a susceptible isolate, clindamycin is an alternative for finite treatment of PJI. Penicillin V or amoxicillin can have a different role in long-term suppression. Activity suitable for suppression does not by itself establish a curative regimen.4 |
Request prolonged anaerobic incubation and interpret multiple specimens in the surgical context. |
Streptococci Native-joint infection and acute hematogenous PJI, sometimes from skin or oral source |
Penicillin/ampicillin or ceftriaxone; cefazolin for susceptible isolates is also reasonable. |
Amoxicillin can be useful for susceptible organisms when oral therapy is appropriate. |
Implant infection still depends heavily on operative strategy. |
Enterococcus PJI or contiguous infection with urinary, gastrointestinal, or healthcare association |
Ampicillin when susceptible; vancomycin when needed. Linezolid or high-dose daptomycin are common VRE options. |
Linezolid has high bioavailability; amoxicillin can be used for susceptible isolates in selected settings. |
Endovascular infection may require a different regimen. |
Enterobacterales Older or immunocompromised host, urinary/intra-abdominal bacteremia, DFO, or postoperative infection |
Ceftriaxone, cefepime, carbapenem, or other active beta-lactam according to resistance mechanism and site. |
Fluoroquinolone or TMP-SMX when susceptible, tolerated, and appropriate. |
ESBL, AmpC, or CRE may change the preferred beta-lactam. |
Pseudomonas aeruginosa Healthcare exposure, penetrating injury, selected injection-drug or water exposures; not a routine empiric target in diabetic foot infection in temperate climates |
Cefepime, ceftazidime, piperacillin-tazobactam, or a newer active agent depending on resistance. |
Ciprofloxacin is the principal established oral antipseudomonal option when susceptible. |
Limited oral options make source control and microbiology especially important. |
Anaerobic / polymicrobial infection Chronic deep diabetic-foot infection, ischemic/necrotic tissue, pressure injury, or contiguous pelvic infection |
Ampicillin-sulbactam, piperacillin-tazobactam, ceftriaxone plus metronidazole, or other tailored regimens. |
Amoxicillin-clavulanate, metronidazole combined with needed aerobic coverage, or other susceptibility-guided options. |
Pressure wounds and diabetic feet can be polymicrobial, but surface flora should not dictate months of therapy. |
Biofilm-active is not a synonym for “add rifampin”
For susceptible staphylococcal retained-prosthesis infection, rifampin combination therapy has a specific evidence base. For gram-negative retained-prosthesis infection, fluoroquinolone activity is valuable when susceptible. For other organisms and drugs, the clinical evidence for “biofilm activity” is much less mature than in-vitro terminology implies.
Oral transition checklist
- Hemodynamics and local infection are stable.
- No undrained abscess or source-control procedure remains immediately necessary.
- No persistent bacteremia. OVIVA excluded S. aureus bacteremia or bacterial endocarditis present at enrollment or within the preceding month; clearance alone does not make those infections eligible for an OVIVA-based oral strategy.
- The oral drug is active and has adequate systemic/site exposure at the intended dose.
- GI absorption and adherence are reliable, and drug interactions are addressed.
- Monitoring is practical. TMP-SMX requires K+, creatinine, and CBC; linezolid requires CBC and longer-course toxicity review; rifampin has major interaction potential.
References 8, 12, 5
Suppression is a treatment intent, not a longer version of curative therapy
Suppressive antimicrobial therapy is reasonable to consider when infected hardware or necrotic bone cannot be removed, curative surgery is too risky or declined, the organism is known, and a tolerable active oral agent exists. The goal is to reduce relapse, symptoms, or additional surgery. It does not sterilize the retained source.
When suppression makes sense
| Question |
Favors suppression |
Argues against suppression |
| Is there a defined target? |
Repeated high-quality deep cultures identify a pathogen with a reliable oral option. |
Culture-negative disease or only superficial wound cultures. |
| Is the retained source finite? |
Stable prosthesis or fixation hardware that cannot currently be removed; extensive necrotic bone not amenable to resection. |
Continuously open contaminated pressure wound without a closure plan. |
| Would recurrence matter? |
Relapse threatens function, hardware survival, hospitalization, or major surgery. |
The drug is unlikely to change symptoms or goals. |
| Can the regimen be sustained? |
Narrow active oral drug, tolerable toxicity profile, feasible labs and follow-up. |
Resistance likely, no oral option, major interactions, recurrent C. difficile, progressive toxicity, or poor adherence. |
Common organism-directed suppressive choices include cephalexin or dicloxacillin for susceptible MSSA, doxycycline/minocycline or TMP-SMX for selected susceptible staphylococci, and a susceptible fluoroquinolone or TMP-SMX for some gram-negative infections. These are examples, not universal defaults. Rifampin monotherapy should not be used for chronic suppression.
The 2026 review pooled 40 studies (2,467 patients) and found 74% reported success overall (95% CI 70–79%). Definitions and populations varied, and selection and survivorship bias limit what the pooled result can tell us about efficacy. Most included US studies intended indefinite suppression. Some studied finite courses. No universal stopping point is established.7
Reassess the decision periodically
At follow-up ask whether the original goal is still being achieved, whether loosening or sinus formation is progressing, whether toxicity or resistance has emerged, and whether surgery has become feasible or desirable.
References 7, 4, 14
The highest-value studies change route and duration, but not the need for source control
OVIVA: oral treatment can replace prolonged IV therapy
OVIVA randomized 1,054 adults to IV or oral therapy for the first 6 weeks; the primary endpoint was definitive treatment failure within 1 year. Failure occurred in 74/506 (14.6%) assessed in the IV group and 67/509 (13.2%) in the oral group. Oral therapy met the prespecified noninferiority criterion. Catheter complications occurred in 9.4% versus 1.0%. Specialist-selected active regimens and suitable source control remain essential. S. aureus bacteremia or endocarditis at presentation or within the previous month was excluded.
DATIPO: six weeks was not enough for all surgically managed PJI
The randomized PJI trial failed to show noninferiority of 6 weeks compared with 12 weeks. The signal was most concerning with retained-implant strategies such as DAIR. It supports avoiding a 6-week DAIR course, but it does not establish one universal duration for every joint or exchange strategy. The 2013 IDSA staphylococcal rifampin-based regimen specifies 3 months for hip and 6 months for knee DAIR.
SOLARIO: very short systemic therapy after definitive surgery plus local antibiotics
SOLARIO randomized 500 adults after definitive curative surgery, implantation of a licensed local-antibiotic carrier with at least 4 weeks of elution, and primary closure; 475 contributed to the primary analysis. Culture-negative cases were eligible, but patients with operative isolates fully resistant to the local antibiotics were excluded from the eligible population. Definite failure at 12 months occurred in 26/234 (11.1%) assigned no more than 7 days of systemic therapy and 34/241 (14.1%) assigned at least 4 weeks (difference −3.0 percentage points; 95% CI −9.0 to 3.0). The prespecified noninferiority margin was 10 percentage points. Antibiotic-related symptoms were less frequent with the short course. DAIR and suppressive procedures were excluded, the cohort combined several orthopedic syndromes, and the PJI subgroups were not separately powered. Do not apply this result to retained infected prostheses or surgery without the same local-antibiotic and closure conditions.
Two versus four weeks after native-joint drainage: useful but anatomically narrow
The randomized trial enrolled 154 cases, 99 involving the hand or wrist. Two weeks after surgical drainage performed well in that population. It is weak justification for shortening treatment of large-joint, bacteremic, axial, or osteomyelitis-complicated infection.
Pressure-injury pelvic osteomyelitis: the evidence is mostly observational
Systematic and multidisciplinary reviews find no evidence that prolonged antibiotics improve outcomes when an open stage IV pressure injury cannot be debrided and closed. Outcomes are poor without flap reconstruction regardless of antibiotics in available cohorts. This is a source-control conclusion, not proof that pelvic osteomyelitis is harmless.
Where the evidence is weakest
Outside specific institutional pathways, optimal PJI duration after one-stage or two-stage exchange, exact rifampin timing, the value of an antibiotic holiday before reimplantation, treatment duration for Brodie abscess, retained fracture fixation, and the benefit/duration of chronic suppression remain incompletely defined.
References 8, 6, 9, 2, 15, 16
Cases: decide the source-control plan before the antibiotic clock
Case 1 · Crystals and a hot knee
A 67-year-old has fever and an acutely swollen native knee. Synovial fluid contains urate crystals and 72,000 WBC/µL with 92% neutrophils.
Discuss the decision
Crystals do not exclude septic arthritis. Send Gram stain/culture and blood cultures, start empiric therapy after aspiration if stable enough to sample first, and obtain urgent orthopedic input for drainage. Narrow to the organism.
Case 2 · Arthritis plus pustules
A young adult has migratory arthralgia, tenosynovitis, pustular lesions, and a swollen ankle.
Discuss the decision
The combination of migratory joint symptoms, tenosynovitis, and pustules raises concern for disseminated gonococcal infection. NAAT from exposed mucosal sites and culture of accessible purulent material help establish the diagnosis; blood cultures may also be informative. Treatment of gonococcal arthritis begins with parenteral ceftriaxone. A single injection for uncomplicated mucosal infection is insufficient. Chlamydia also needs treatment if it has not been excluded, with drug selection and follow-up appropriate to pregnancy status. For arthritis-dermatitis syndrome, an active oral option may be used 24–48 hours after substantial clinical improvement if susceptibility testing supports it. Total therapy is at least 7 days.
Case 3 · Acute postoperative knee PJI
Three weeks after TKA, the patient develops 3 days of pain, effusion, and drainage. Components are well fixed. Aspiration grows MSSA.
Discuss the decision
Three days of symptoms and a fixed prosthesis favor DAIR if there is no sinus tract and the soft tissue is suitable. Debridement, exchange of modular components when feasible, and multiple deep cultures support that strategy. For this susceptible staphylococcal knee infection, the historical rifampin-based regimen totals 6 months. The oral switch depends on response and a suitable companion drug; after debridement, rifampin must be used with another active agent.4
Case 4 · Chronic hip PJI considered for one-stage exchange
A patient has months of hip pain, a well-fixed prosthesis, good soft tissue, no sinus tract, and repeated deep aspiration cultures growing susceptible Cutibacterium acnes.
Discuss the decision
Repeated isolation of a susceptible organism and a favorable soft-tissue envelope make one-stage exchange a reasonable consideration. This operation combines removal of infected components, radical debridement, separate deep samples (at least five when feasible), and implantation of the new prosthesis. The operative cultures guide subsequent therapy. For a nonstaphylococcal infection such as this, the historical regimen is 4–6 weeks of IV or highly bioavailable oral therapy, without a fixed IV lead-in. Indefinite suppression serves a different purpose.4,5
Case 5 · Stable vertebral osteomyelitis with negative blood cultures
A stable patient has severe back pain and MRI findings compatible with L2–L3 discitis/osteomyelitis. Neurologic examination is normal and blood cultures are negative.
Discuss the decision
The stable examination provides time for image-guided biopsy before empiric therapy, both to identify the organism and to assess other causes of the MRI findings. Most confirmed bacterial native vertebral infections respond to 6 weeks of parenteral or highly bioavailable oral treatment. Repeat MRI is usually unnecessary when the patient improves.13
Case 6 · Months of tibial pain and a Brodie-type lesion
A 24-year-old has focal tibial pain for 3 months, no fever, normal WBC, and a well-circumscribed intramedullary lesion.
Discuss the decision
Subacute osteomyelitis is possible, but malignancy and other mimics matter. Orthopedic curettage/biopsy provides diagnosis, cultures, histology, and source control. Published cases used antibiotic courses from 10 days to more than 3 months. Use cultures, the operative findings, and the adequacy of source control to individualize therapy. The optimal duration is unclear.17
Case 7 · Stage IV sacral wound, exposed bone, MRI “osteomyelitis,” no flap option
A chronically immobile patient has an open sacral pressure injury with visible bone. There is no surrounding cellulitis, abscess, fever, bacteremia, or hemodynamic instability. Plastics determines durable flap closure is not feasible.
Discuss the decision
The wound is open, durable closure is not feasible, and there is no acute soft-tissue or systemic infection. In that setting, exposed bone and MRI changes do not justify six weeks of antibiotics, repeated courses, or chronic suppression. Pressure relief, moisture and wound care, debridement when appropriate, nutrition, and pain or odor control address the problems the patient actually has. A new cellulitis, abscess, bacteremia, or sepsis would be a separate indication for treatment.15,16
Case 8 · The same wound, now septic with a gluteal abscess
The patient later develops fever, hypotension, spreading erythema, and CT evidence of a drainable gluteal collection.
Discuss the decision
Hypotension and a drainable collection change the question. This patient needs prompt antibiotics and abscess drainage, with blood and deep cultures when feasible. Severity and prior resistance inform initial coverage; cultures guide narrowing. The duration addresses the acute infection and the adequacy of drainage. The chronic sacral MRI finding does not, by itself, indicate six weeks of treatment.16
Case 9 · Diabetic forefoot osteomyelitis after toe amputation
A patient undergoes minor amputation for infected toe osteomyelitis. The remaining bone-margin culture is positive.
Discuss the decision
The positive margin raises concern for residual bone infection. After minor amputation in this setting, up to 3 weeks is suggested, based on limited evidence. Complete resection with no residual infection is a different situation, for which foot guidance lists 2–5 days. Offloading, wound care, glycemic management, and assessment of perfusion remain part of treatment in either case.14
Check the reasoning
1. Do urate crystals exclude septic arthritis?
Show explanation
No. Crystal disease and bacterial arthritis can coexist.
2. What is the highest-value action in a purulent native knee?
Show explanation
Prompt diagnostic sampling and effective drainage, with timely active antibiotics. Antibiotics do not substitute for drainage.
3. Does every acute PJI qualify for DAIR?
Show explanation
No. Implant stability, symptom duration, sinus tract, soft tissue, pathogen, host factors, and ability to exchange modular parts all affect the likelihood of cure.
4. Is rifampin a general add-on for any staphylococcal bone infection?
Show explanation
No. Its strongest clinical role is susceptible staphylococcal infection with retained prosthetic material in combination with another active agent. Never use it alone.
5. Does osteomyelitis require six weeks of IV therapy?
Show explanation
No. Duration and route are different decisions. With adequate source control and no retained implant, evidence supports a maximum of 6 weeks for typical pyogenic osteomyelitis; selected patients can receive an active, adequately absorbed oral agent. Complete resection raises a separate, less certain question that depends on the site, the operation, and any residual infection.12,8,14
6. Does exposed sacral bone prove osteomyelitis?
Show explanation
No. Chronic exposed bone can show remodeling without histologic osteomyelitis, and MRI can overcall infection in this setting.
7. What should an asymptomatic open sacral wound with suspected pelvic osteomyelitis receive if there is no debridement/flap plan?
Show explanation
No systemic antibiotics for the osteomyelitis label alone. Treat acute soft-tissue or systemic infections when present and focus on wound/pressure management.
8. When is chronic suppression most defensible?
Show explanation
When a defined infection source such as retained prosthetic hardware cannot be removed, a known pathogen has a tolerable active oral option, and preventing relapse or further surgery is a meaningful patient goal.
9. Should worsening vertebral MRI at week 6 automatically extend antibiotics?
Show explanation
No. If pain, examination, and inflammatory markers are improving, imaging can lag behind clinical cure.
10. What is the central documentation sentence?
Show explanation
State the infected structure, source control completed or impossible, microbiologic target, treatment intent, and what event determines duration.
A good consult plan makes the source-control logic visible
Suggested documentation
[Native joint / prosthetic joint / bone / vertebral / pressure-injury pelvic infection] involving [site]. Tempo is [acute/subacute/chronic], but duration will be determined by [source-control strategy and retained material], not tempo alone.
Diagnostic evidence: [blood / synovial / deep tissue / bone cultures, histology, imaging]. The microbiologic target is [organism], with [important susceptibility/biofilm issue]. Avoid relying on [surface wound/sinus culture] for definitive therapy.
Source control: [aspiration/lavage/debridement/DAIR with modular exchange/one-stage/two-stage/resection/flap/drainage] is [completed/planned/not feasible]. Residual infected material is [none / prosthesis / fixation hardware / necrotic bone / open wound].
Antibiotics: [drug, dose/route] because [pathogen/site/exposure]. Oral transition is appropriate when [criteria]. Planned curative duration is [duration] from [debridement/source control/effective therapy as appropriate]. If suppression is planned, document that intent explicitly as noncurative and define the goal, monitoring, and reassessment plan.
Non-ID plan: [orthopedics/spine/plastics/wound care/podiatry/vascular], [pressure offloading or weight-bearing plan], [wound/flap plan], [nutrition/perfusion/glycemic/rehab issues].
Reassess on [date/event] for [clinical response, cultures, wound status, hardware stability, toxicity, need for further source control].
Bone and joint infections · One-page rounds sheet
Teaching companion · Edited November 10, 2026.
Native septic arthritis
Aspirate before antibiotics if stable. Send culture, WBC/diff, crystals. Crystals do not exclude infection. Drain the joint. Choose empiric staphylococcal and gram-negative coverage from Gram stain, MRSA risk, host factors, and local epidemiology; add antipseudomonal coverage when risk warrants.
PJI diagnosis
Sinus tract to prosthesis = PJI. If stable, avoid premature antibiotics. Aspirate when useful. At surgery collect deep samples. EBJIS advises at least 5. IDSA advises at least 3, ideally 5–6. Do not use superficial sinus/wound swab to choose long-term therapy.
PJI surgery
DAIR: acute, brief symptoms, fixed implant, no sinus, good tissue, exchange modular parts. One-stage: selected chronic PJI with known/tractable organism and good tissue. Two-stage: chronic/difficult infection, compromised tissue, or failed retention.
PJI antibiotics
The archived staphylococcal DAIR regimen used 2–6 weeks of IV therapy with rifampin, then rifampin with an active oral companion to total 3 months for a hip or 6 months for a knee. One-stage courses depend on the organism and regimen. After staged explantation, 4–6 weeks of IV or highly bioavailable oral therapy is typical. There is no established mandatory antibiotic-free interval. Interpret reimplantation cultures in context and give indicated perioperative prophylaxis.4,5
Osteomyelitis, no implant
Adequate source control and absence of an implant are the conditions behind the six-week maximum for typical pyogenic osteomyelitis. After complete resection, evidence for omitting further bone-directed therapy is limited; diabetic foot guidance suggests 2–5 days. Residual infection or bacteremia changes the assessment.12,14
Vertebral osteomyelitis
Neurologic compromise requires immediate spine surgical evaluation and empiric therapy. Sepsis or shock requires prompt empiric therapy. Stable hemodynamics and a normal, stable neurologic examination may allow time for microbiologic diagnosis first. Most bacterial native vertebral infections receive 6 weeks of therapy.13
Diabetic foot
For diabetic foot osteomyelitis, consider 6 weeks without bone resection or up to 3 weeks after minor amputation with positive bone-margin culture. Urgent surgical input is needed for severe infection or moderate infection with extensive gangrene, necrotizing infection, suspected deep abscess, compartment syndrome, or severe ischemia. An infected ulcer or gangrene with PAD needs urgent surgical and vascular input. Continue wound care and offloading.14
Stage IV sacral/pelvic wound
Exposed bone or MRI “OM” without acute infection and without debridement/flap plan = no systemic antibiotics. Treat discrete cellulitis, abscess, bacteremia, or sepsis. If debridement + flap occurs, ~6 weeks remains conventional.
Oral therapy
OVIVA supports oral treatment when stable, source controlled, absorbing reliably, and an active evidence-supported oral drug is available. Osteomyelitis does not automatically require a PICC.
Suppression
Noncurative. Best fit: defined pathogen + retained hardware/necrotic source that cannot be removed + tolerable active oral drug + meaningful goal. Do not routinely suppress an open sacral pressure wound.